Učitavanje...
Targeting RAS-mutant cancers: is ERK the key?
The three RAS genes comprise the most frequently mutated oncogene family in cancer. With significant and compelling evidence that continued function of mutant RAS is required for tumor maintenance, it is widely accepted that effective anti-RAS therapy will have a significant impact on cancer growth...
Spremljeno u:
| Izdano u: | Trends Cancer |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4743050/ https://ncbi.nlm.nih.gov/pubmed/26858988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trecan.2015.10.001 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|